Gastric cancer is the third greatest global cause of cancer-related deaths. Despite its high prevalence, only recently have comprehensive genomic surveys shed light on its molecular alterations. As surgery is the only curative treatment strategy and chemotherapy has shown limited efficacy, new treatments are urgently needed. Many molecular therapies for gastric cancer have entered clinical trials but-apart from Trastuzumab and Ramucirumab-all have failed. We analyze the current knowledge of the genetic 'landscape' of gastric cancers, elaborating on novel, preclinical approaches. We posit that this knowledge lays the basis for identifying bona fide molecular targets and developing solid therapeutic approaches, requiring accurate patient selection and taking advantage of preclinical models to assist clinical development of novel combination strategies.

How Can Gastric Cancer Molecular Profiling Guide Future Therapies?

CORSO, Simona
First
;
GIORDANO, Silvia
Last
2016-01-01

Abstract

Gastric cancer is the third greatest global cause of cancer-related deaths. Despite its high prevalence, only recently have comprehensive genomic surveys shed light on its molecular alterations. As surgery is the only curative treatment strategy and chemotherapy has shown limited efficacy, new treatments are urgently needed. Many molecular therapies for gastric cancer have entered clinical trials but-apart from Trastuzumab and Ramucirumab-all have failed. We analyze the current knowledge of the genetic 'landscape' of gastric cancers, elaborating on novel, preclinical approaches. We posit that this knowledge lays the basis for identifying bona fide molecular targets and developing solid therapeutic approaches, requiring accurate patient selection and taking advantage of preclinical models to assist clinical development of novel combination strategies.
2016
22
7
534
544
http://www.sciencedirect.com/science/article/pii/S1471491416300284
HER2; gastric cancer; targeted therapies; tyrosine kinase receptors
Corso, Simona; Giordano, Silvia
File in questo prodotto:
File Dimensione Formato  
2016_How Can Gastric Cancer Molecular Profiling Guide Future Therapies.pdf

Accesso riservato

Descrizione: Trends Mol Med_RISERVATO
Tipo di file: PDF EDITORIALE
Dimensione 2.18 MB
Formato Adobe PDF
2.18 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
2016_trans mol med_aperto.pdf

Accesso aperto

Descrizione: Trends Mol Med_APERTO
Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 442.8 kB
Formato Adobe PDF
442.8 kB Adobe PDF Visualizza/Apri
1-s2.0-S1471491416300284-main.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 2.29 MB
Formato Adobe PDF
2.29 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1565043
Citazioni
  • ???jsp.display-item.citation.pmc??? 24
  • Scopus 50
  • ???jsp.display-item.citation.isi??? 48
social impact